GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

C.Q. Pharmaceutical Holding Co 000950.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

5.08

-0.97%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥82.45bn

FY2016FY2025

Net income

CN¥386.7m

FY2016FY2025

Free cash flow

CN¥455.1m

FY2016FY2025

Shareholders' equity

CN¥11.54bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥82.45bnCN¥80.56bnCN¥78.40bnCN¥67.83bnCN¥62.52bnCN¥45.22bnCN¥33.84bnCN¥25.80bnCN¥21.19bnCN¥20.49bn
Gross profitCN¥5.94bnCN¥5.92bnCN¥6.24bnCN¥5.79bnCN¥5.70bnCN¥4.21bnCN¥3.04bnCN¥2.29bnCN¥2.22bnCN¥1.86bn
Research and developmentCN¥469,748CN¥6.0mCN¥383,333CN¥3.2mCN¥10.0mCN¥2.7mCN¥2.9mCN¥243,393CN¥2,253CN¥6.5m
Operating incomeCN¥1.91bnCN¥562.6mCN¥964.9mCN¥1.44bnCN¥1.56bnCN¥1.37bnCN¥1.12bnCN¥846.7mCN¥1.26bnCN¥630.9m
Net incomeCN¥386.7mCN¥283.0mCN¥624.6mCN¥952.3mCN¥1.01bnCN¥884.3mCN¥788.0mCN¥690.7mCN¥1.11bnCN¥955.8m
Diluted earnings per share0.230.150.350.550.590.530.470.40569.95-0.72

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥66.24bnCN¥66.63bnCN¥63.52bnCN¥57.19bnCN¥49.70bnCN¥42.43bnCN¥25.48bnCN¥20.11bnCN¥15.20bnCN¥5.46bn
Cash and short-term investments—CN¥9.39bnCN¥9.15bnCN¥7.43bnCN¥5.68bnCN¥4.69bnCN¥3.36bnCN¥2.55bnCN¥1.92bnCN¥261.5m
Total liabilitiesCN¥49.69bnCN¥50.17bnCN¥48.02bnCN¥44.48bnCN¥37.93bnCN¥31.95bnCN¥16.62bnCN¥12.01bnCN¥7.95bnCN¥4.42bn
DebtCN¥2.43bnCN¥20.86bnCN¥23.09bnCN¥22.12bnCN¥18.20bnCN¥15.32bnCN¥6.72bnCN¥4.15bnCN¥879.4mCN¥2.39bn
Shareholders' equityCN¥11.54bnCN¥11.33bnCN¥11.25bnCN¥10.65bnCN¥9.82bnCN¥8.84bnCN¥8.07bnCN¥7.32bnCN¥6.72bnCN¥1.04bn
Shares outstanding1,708m1,918m1,764m1,727m1,692m1,669m1,682m1,743m2m—

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥754.7m−CN¥186.7mCN¥508.5mCN¥285.8mCN¥250.2mCN¥632.0mCN¥202.4m−CN¥1.71bn−CN¥1.10bnCN¥247.5m
Capital spending−CN¥299.5m−CN¥250.5m−CN¥244.4m−CN¥268.1m−CN¥489.5m−CN¥378.2m−CN¥821.4m−CN¥304.0m−CN¥151.4m−CN¥141.3m
Free cash flowCN¥455.1m−CN¥437.3mCN¥264.1mCN¥17.8m−CN¥239.4mCN¥253.8m−CN¥619.0m−CN¥2.01bn−CN¥1.25bnCN¥106.2m
Dividends paid−CN¥873.6m−CN¥1.12bn−CN¥1.30bn−CN¥112.4m−CN¥69.1m−CN¥86.4m−CN¥275.4m−CN¥127.0m−CN¥122.9m−CN¥183.9m

Latest quarters

By quarter end

Sept 2026Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024
RevenueCN¥20.14bnCN¥19.70bnCN¥20.43bnCN¥20.24bnCN¥21.02bnCN¥20.58bnCN¥20.61bnCN¥20.87bn
Gross profitCN¥1.39bnCN¥1.33bnCN¥1.40bnCN¥1.45bnCN¥1.49bnCN¥1.52bnCN¥1.48bnCN¥1.48bn
Operating incomeCN¥434.1mCN¥408.0mCN¥550.3mCN¥239.0mCN¥193.8mCN¥257.4mCN¥214.0mCN¥14.6m
Net incomeCN¥66.1mCN¥83.7mCN¥170.7mCN¥2.7mCN¥101.7mCN¥157.0mCN¥125.2m−CN¥9.2m
Diluted earnings per share0.040.050.100.000.060.090.07-0.00
Cash from operations————−CN¥56.0m−CN¥108.0m−CN¥2.16bnCN¥2.96bn
Capital spending−CN¥52.0m−CN¥82.0m−CN¥99.0m−CN¥92.0m−CN¥75.0m−CN¥50.0m−CN¥80.0m−CN¥101.0m
Free cash flow————−CN¥131.0m−CN¥158.0m−CN¥2.24bnCN¥2.86bn
Total assetsCN¥67.47bnCN¥68.08bnCN¥68.80bnCN¥66.24bnCN¥67.71bnCN¥67.95bnCN¥68.50bnCN¥66.63bn
Cash and short-term investments————CN¥5.31bnCN¥6.29bnCN¥6.97bnCN¥9.39bn
DebtCN¥1.83bnCN¥1.36bnCN¥1.91bnCN¥2.43bnCN¥23.23bnCN¥21.46bnCN¥19.97bnCN¥20.60bn
Shareholders' equityCN¥11.81bnCN¥11.74bnCN¥11.71bnCN¥11.54bnCN¥11.56bnCN¥11.53bnCN¥11.44bnCN¥11.33bn

Financial ratios

Data as of 6 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin7.2%7.3%8.0%8.5%9.1%9.3%
Operating margin1.7%2.1%2.9%3.8%4.3%4.7%
Net margin0.5%0.4%0.8%1.4%1.6%2.0%
Return on equity3.4%2.5%5.6%8.9%10.2%10.0%
Return on assets0.6%0.4%1.0%1.7%2.0%2.1%
Free cash flow yield11.8%0.6%8.1%6.1%8.3%11.5%
Revenue growth2.3%2.8%15.6%8.5%38.3%33.6%
Earnings growth36.7%-54.7%-34.4%-5.3%13.7%12.2%
Current ratio1.22x1.30x1.27x1.20x1.30x1.29x
Debt to equity0.21x1.82x2.03x2.05x1.83x1.95x
Equity ratio17.4%17.0%17.7%18.6%19.8%20.8%
Interest coverage1.89x1.49x1.72x2.31x2.43x2.86x
R&D as a share of sales0.0%0.0%0.0%0.0%0.0%0.0%
Buybacks as a share of market value10.9%-8.7%-2.2%-2.1%-1.4%0.8%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.7%12.8%15.6%
Operating income10.1%6.9%22.0%
Net income-25.9%-15.2%-0.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin7.3%7.7%8.1%8.4%
Operating margin1.5%1.6%1.9%2.2%
Net margin0.4%0.7%1.0%1.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings25.736.514.09.28.69.812.312.70.0-13.0
Price to sales0.10.10.10.10.10.20.30.3—-0.6

Dividends and splits

Per share, in the currency the company pays

Paid for 6 years. Last went ex-dividend on 18 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2012
Paid in the year0.030.060.080.060.0650.040.050.15
  • 3-for-2 split · 16 Apr 2010
  • 5-for-4 split · 23 Apr 2008
  • 1-to-1 reverse split · 27 Dec 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.